(GRTS) – Globe Newswire
-
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
-
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
-
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
-
Gritstone bio Announces Proposed Public Offering
-
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vacci
-
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
-
Gritstone bio Announces Workforce Reduction
-
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
-
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio to Participate in Upcoming Investor Conference
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio to Participate in Upcoming Investor Conferences
-
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA Award
-
Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023
-
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio to Participate in Upcoming Investor Conferences
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio and Genevant Sciences Announce Option and License Agreement
-
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
-
Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio Announces Publication of Interim Results from Phase 1 Study of Self-amplifying mRNA (samRNA) Vaccine Against COVID-19 in Nature Communications
-
Gritstone bio to Participate in Upcoming Investor Conferences
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates
-
Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)
-
Gritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual Meeting
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023
-
Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting
-
Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
-
Gritstone bio to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 9, 2023
-
Gritstone bio to Participate in 43rd Annual Cowen Healthcare Conference
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination
-
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio to Participate in Upcoming Investor Conferences
-
Gritstone bio to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)
-
Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors
Back to GRTS Stock Lookup
